Literature DB >> 3800348

Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin.

N K Henry, W R Wilson, J E Geraci.   

Abstract

We used two strains of streptomycin-susceptible enterococci (MIC, 64 and 128 micrograms of streptomycin per ml, respectively) isolated from patients with infective endocarditis. When combined with penicillin, 20 micrograms of streptomycin per ml killed both strains synergistically in vitro whereas combinations of 5 and 10 micrograms of streptomycin per ml did not act synergistically against either strain. By using the rabbit model of enterococcal experimental endocarditis, animals were treated for 3 days with procaine penicillin (1.2 X 10(6) U intramuscularly three times daily) together with low-dose streptomycin (3.5 mg/kg) or high-dose streptomycin (10 mg/kg) intramuscularly three times daily. The peak concentrations of streptomycin in serum at 0.5 h were 9.2 and 26.8 micrograms/ml in the low- or high-dose group, respectively. When combined with procaine penicillin, both dosages of streptomycin were more effective (P less than 0.01) than procaine penicillin alone for the treatment of enterococcal experimental endocarditis. There was no significant difference in the efficacy of procaine penicillin plus low-dose streptomycin versus procaine penicillin plus high-dose streptomycin therapy of enterococcal experimental endocarditis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3800348      PMCID: PMC176521          DOI: 10.1128/AAC.30.5.725

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases.

Authors:  J E GERACI; W J MARTIN
Journal:  Circulation       Date:  1954-08       Impact factor: 29.690

2.  Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis.

Authors:  J Y Matsumoto; W R Wilson; A J Wright; J E Geraci; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

3.  Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis.

Authors:  W R Wilson; C J Wilkowske; A J Wright; M A Sande; J E Geraci
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

4.  Optimal therapy for enterococcal endocarditis.

Authors:  J Herzstein; J L Ryan; R J Mangi; T P Greco; V T Andriole
Journal:  Am J Med       Date:  1984-02       Impact factor: 4.965

5.  Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis.

Authors:  W M Scheld; J M Keeley
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

6.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

Review 7.  Combination antibiotic therapy of bacterial endocarditis.

Authors:  M A Sande; W M Scheld
Journal:  Ann Intern Med       Date:  1980-03       Impact factor: 25.391

8.  Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis.

Authors:  J Carrizosa; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

9.  Enterococcal endocarditis.

Authors:  C J Wilkowske
Journal:  Mayo Clin Proc       Date:  1982-02       Impact factor: 7.616

10.  Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart.

Authors:  P K Garrison; L R Freedman
Journal:  Yale J Biol Med       Date:  1970-06
  10 in total
  4 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 3.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

4.  Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.